Free Trial
OTCMKTS:EDTXF

Spectral Diagnostics 11/7/2025 Earnings Report

Spectral Diagnostics logo
$1.03 +0.01 (+0.78%)
As of 03:22 PM Eastern

Spectral Diagnostics EPS Results

Actual EPS
-$0.08
Consensus EPS
-$0.01
Beat/Miss
Missed by -$0.07
One Year Ago EPS
N/A

Spectral Diagnostics Revenue Results

Actual Revenue
$0.49 million
Expected Revenue
$0.54 million
Beat/Miss
Missed by -$56.00 thousand
YoY Revenue Growth
N/A

Spectral Diagnostics Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Spectral Diagnostics' next earnings date is estimated for Friday, May 8, 2026, based on past reporting schedules.

Conference Call Resources

Spectral Diagnostics Earnings Headlines

Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.tc pixel
See More Spectral Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Spectral Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spectral Diagnostics and other key companies, straight to your email.

About Spectral Diagnostics

Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics (OTCMKTS:EDTXF) and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.

View Spectral Diagnostics Profile